<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="apt15779-tbl-0003" xml:lang="en" content-type="Table" orientation="portrait" position="float">
 <label>Table 3</label>
 <caption>
  <p>Half‐life elimination of IBD medications</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="top">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="top" rowspan="1" colspan="1">Drug</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Half‐life and time to reach therapeutic effect</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Elimination half‐life (Most drugs considered to have negligible effect after four‐to‐five half‐lives)</th>
    <th align="left" valign="top" rowspan="1" colspan="1">
     <p>How long the immunosuppression lasts</p>
     <p>50% drug eliminated after one elimination half‐lives</p>
     <p>75% drug eliminated after two elimination half‐lives</p>
     <p>99% drug eliminated after seven elimination half‐lives</p>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">Thiopurines (Azathioprine and Mercaptopurine)</td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <italic>t</italic>
      <sub>1/2</sub>:6‐TGN and 6‐MMP in RBC = 5 days
      <xref rid="apt15779-bib-0124" ref-type="ref">
       <sup>124</sup>
      </xref>
     </p>
     <p>Steady state: 6‐TGN and 6‐MMP = 4 weeks in RBC
      <xref rid="apt15779-bib-0124" ref-type="ref">
       <sup>124</sup>
      </xref>
     </p>
     <p>Median time to clinical response: 4.5 months
      <xref rid="apt15779-bib-0125" ref-type="ref">
       <sup>125</sup>
      </xref>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">6‐TGN in RBC: 6.8 days [IQR 5.9‐8.4 days]
     <xref rid="apt15779-bib-0126" ref-type="ref">
      <sup>126</sup>
     </xref>, 
     <xref ref-type="fn" rid="apt15779-note-0004">
      <sup>a</sup>
     </xref>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>75% of 6‐TGN eliminated after 10‐14 days and expected to be negligible by day 40.
      <xref rid="apt15779-bib-0126" ref-type="ref">
       <sup>126</sup>
      </xref>
     </p>
     <p>Immune reconstitution occurs quickly after thiopurine cessation, if the antigen was not encountered whilst on the thiopurine therapy.
      <xref rid="apt15779-bib-0126" ref-type="ref">
       <sup>126</sup>
      </xref>
     </p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Adalimumab</td>
    <td align="left" rowspan="1" colspan="1">The subcutaneous injection has a bioavailability of 64% and peak drug concentration at day 5 following injection
     <xref rid="apt15779-bib-0127" ref-type="ref">
      <sup>127</sup>
     </xref>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>17.8‐23.9 days (in RA population)
      <xref rid="apt15779-bib-0128" ref-type="ref">
       <sup>128</sup>
      </xref>
     </p>
     <p>Clearance of 0.33L/day
      <xref rid="apt15779-bib-0013" ref-type="ref">
       <sup>13</sup>
      </xref>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">75% eliminated after approximately 40 days</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Infliximab</td>
    <td align="left" rowspan="1" colspan="1">IV infusion 8‐9.5 days</td>
    <td align="left" rowspan="1" colspan="1">7‐12 days 
     <xref rid="apt15779-bib-0129" ref-type="ref">
      <sup>129</sup>
     </xref>, 
     <xref rid="apt15779-bib-0130" ref-type="ref">
      <sup>130</sup>
     </xref>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>75% eliminated after 2‐3 weeks</p>
     <p>Low volume of distribution (3‐6L/kg) and very low systemic clearance of 11‐15ml/hr, mean infliximab is predominantly in the intravascular space for 12‐17 days prior to elimination
      <xref rid="apt15779-bib-0129" ref-type="ref">
       <sup>129</sup>
      </xref>, 
      <xref rid="apt15779-bib-0130" ref-type="ref">
       <sup>130</sup>
      </xref>
     </p>
     <p>Low albumin and higher body weight will speed up elimination
      <xref rid="apt15779-bib-0131" ref-type="ref">
       <sup>131</sup>
      </xref>
     </p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Tofacitinib</td>
    <td align="left" rowspan="1" colspan="1">3‐3.8 hours</td>
    <td align="left" rowspan="1" colspan="1">3 hours</td>
    <td align="left" rowspan="1" colspan="1">
     <p>After a single dose, 95% is expected to be eliminated within 24 hours.</p>
     <p>Pharmacodynamic effects generally reversible in 14 days after discontinuation</p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Methotrexate</td>
    <td align="left" rowspan="1" colspan="1">Methotrexate in serum has a half‐life of 6 hours but is converted quickly to methotrexate polyglutamate which is stored for much longer in liver and erythrocytes.
     <xref rid="apt15779-bib-0132" ref-type="ref">
      <sup>132</sup>
     </xref>
    </td>
    <td align="left" rowspan="1" colspan="1">3‐10 hours (for methotrexate, not activity)</td>
    <td align="left" rowspan="1" colspan="1">75% of methotrexate eliminated by within 24 hours but effect continues through active metabolites.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Ustekinumab</td>
    <td align="left" rowspan="1" colspan="1">First dose given IV to reach peak concentration</td>
    <td align="left" rowspan="1" colspan="1">19 days</td>
    <td align="left" rowspan="1" colspan="1">
     <p>Eliminated at 0.19 L/day (IBD)</p>
     <p>75% eliminated by 38 days</p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Golimumab</td>
    <td align="left" rowspan="1" colspan="1">2‐2.3 days (RA Populations) 
     <xref rid="apt15779-bib-0128" ref-type="ref">
      <sup>128</sup>
     </xref>
    </td>
    <td align="left" rowspan="1" colspan="1">14 days</td>
    <td align="left" rowspan="1" colspan="1">
     <p>Clearance 7.6 mL/kg/kg</p>
     <p>75% eliminated by approx. 30 days</p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Vedolizumab</td>
    <td align="left" rowspan="1" colspan="1">Although given intravenously, clinical effect can takes weeks</td>
    <td align="left" rowspan="1" colspan="1">25 days</td>
    <td align="left" rowspan="1" colspan="1">
     <p>Cleared at 0.157 L/day</p>
     <p>75% eliminated by 50 days</p>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="apt15779-ntgp-0003">
  <fn id="apt15779-note-0004">
   <label>
    <sup>a</sup>
   </label>
   <p>Low numbers, n = 9 with missing data.
    <xref rid="apt15779-bib-0126" ref-type="ref">
     <sup>126</sup>
    </xref>
   </p>
  </fn>
 </table-wrap-foot>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
  <license>
   <license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
  </license>
 </permissions>
</table-wrap>
